Published on
Apr 14, 2026
<![CDATA[Q&A: Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C by 65% in Phase 3 Trial, With Ann Marie Navar, MD, PhD]]>
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the United States, and aggressive LDL cholesterol (LDL-C) reduction is a central pillar of prevention. Contemporary guidelines increasingly call for LDL- …
Source:
Patient Care
-
Pending
